Edition:
India

Dechra Pharmaceuticals PLC (DPH.L)

DPH.L on London Stock Exchange

2,986.00GBp
23 Aug 2019
Change (% chg)

50.00 (+1.70%)
Prev Close
2,936.00
Open
2,964.00
Day's High
3,000.00
Day's Low
2,936.00
Volume
150,357
Avg. Vol
169,524
52-wk High
3,163.00
52-wk Low
1,992.00

Latest Key Developments (Source: Significant Developments)

Dechra Pharmaceuticals Buys Further 15% Issued Share Capital Of Medical Ethics
Friday, 5 Jul 2019 

July 5 (Reuters) - Dechra Pharmaceuticals PLC ::INCREASED INVESTMENT IN MEDICAL ETHICS.ACQUIRED A FURTHER 15.0% OF ISSUED SHARE CAPITAL OF MEDICAL ETHICS PTY LTD.PROPOSED DEAL FOR TOTAL CONSIDERATION OF C.AUD$13.5 MILLION.FOLLOWING ACQUISITION, DECHRA WILL HOLD 48.0% OF ISSUED SHARE CAPITAL OF MEDICAL ETHICS.  Full Article

Dechra Pharma HY Net Revenue Up By About 18 Pct
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Dechra Pharmaceuticals PLC ::DECHRA PHARMACEUTICALS PLC - TRADING IN PERIOD WAS STRONG AND IN LINE WITH MANAGEMENT EXPECTATIONS.DECHRA PHARMACEUTICALS PLC - HY REPORTED GROUP NET REVENUE FOR PERIOD INCREASED BY C.18% AT CONSTANT EXCHANGE RATES.DECHRA PHARMACEUTICALS PLC - HY EUROPEAN PHARMACEUTICALS NET REVENUE GROWTH WAS C.18% AT CER IN PERIOD.DECHRA PHARMACEUTICALS PLC - BREXIT CONTINGENCY PREPARATIONS ARE PROGRESSING WELL TOWARDS COMPLETION AHEAD OF 29 MARCH 2019.DECHRA PHARMACEUTICALS PLC - BREXIT CONTINGENCY PREPARATIONS IN LINE WITH EXISTING SCOPE/COST EXPECTATIONS.DECHRA PHARMACEUTICALS PLC - HY NORTH AMERICAN PHARMACEUTICALS NET REVENUE GROWTH WAS C.18% AT CER IN PERIOD.  Full Article

Dechra Buys Trade, Assets Of Caledonian Holdings For 4.4 Mln Stg
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Dechra Pharmaceuticals PLC ::ACQUISITION OF TRADE AND ASSETS OF CALEDONIAN HOLDINGS FOR A CASH CONSIDERATION OF NZD 8.7 MILLION (£4.4M).  Full Article

Dechra Pharmaceuticals Says HY Revenue Up 11 Pct
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Dechra Pharmaceuticals Plc ::SAYS REPORTED GROUP REVENUE FOR SIX MONTHS ENDED 31 DECEMBER 2017 INCREASED BY 11.2% AT CONSTANT EXCHANGE RATE.SAYS EUROPEAN PHARMACEUTICALS REVENUE GROWTH WAS 5.8% AT CONSTANT EXCHANGE RATE FOR SIX MONTHS ENDED 31 DECEMBER 2017.DECHRA PHARMACEUTICALS - NORTH AMERICAN PHARMACEUTICALS REVENUE GROWTH WAS 20.7% AT CONSTANT EXCHANGE RATE FOR SIX MONTHS ENDED 31 DECEMBER 2017.DECHRA PHARMACEUTICALS - ‍HY UNDERLYING OPERATING PROFIT GROWTH OF 22.3% AT CER (22.6% AT AER) WITH OPERATING MARGIN EXPANSION OF 220 BPS TO 24.6%​.‍HY UNDERLYING DILUTED EPS GROWTH OF 19.8% TO 37.58 PENCE​.HY ‍UNDERLYING PROFIT BEFORE TAXATION INCREASED BY 17.6% AT CER TO £44.3 MILLION​.‍DECLARE AN INTERIM DIVIDEND OF 7.33 PENCE PER SHARE​.‍CURRENT TRADING CONTINUES IN LINE WITH MANAGEMENT EXPECTATIONS​.  Full Article

Dechra Says ‍Trading In Line With Management Expectations
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Dechra Pharmaceuticals Plc ::‍TRADING IN PERIOD WAS STRONG AND IN LINE WITH MANAGEMENT EXPECTATIONS​.‍REPORTED GROUP REVENUE FOR PERIOD INCREASED BY C.10.5% AT CONSTANT EXCHANGE RATE (CER) (C.11.5% AT ACTUAL EXCHANGE RATE (AER))​.  Full Article

Dechra Pharmaceuticals ‍Q1 performance in line with management expectations
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Dechra Pharmaceuticals Plc ::DECHRA PHARMACEUTICALS - ‍ PERFORMANCE IN Q1 OF FINANCIAL YEAR WAS IN LINE WITH MANAGEMENT EXPECTATIONS, WITH CONTINUED GROWTH ACROSS ALL OF ITS MARKETS​.  Full Article